Investigating how long to cool children after cardiac arrest to improve brain recovery
1/2 Pediatric Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
This study is looking at how long to cool the bodies of children who have had a cardiac arrest outside of the hospital to help protect their brains and improve their chances of surviving and recovering well.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10922751 on NIH RePORTER |
What this research studies
This research focuses on children who experience out-of-hospital cardiac arrest (OHCA), a serious condition that can lead to death or severe brain injury. The study aims to determine the optimal duration of therapeutic hypothermia, a treatment that involves cooling the body to protect the brain after resuscitation. By comparing different cooling durations, the researchers hope to find a method that enhances survival rates and neurological recovery in pediatric patients. The effectiveness of this approach will be measured using specific behavioral assessments to evaluate improvements in adaptive behaviors.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0 to 21 who have experienced out-of-hospital cardiac arrest.
Not a fit: Patients who have not experienced cardiac arrest or those with pre-existing severe neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better survival rates and improved brain function in children who have suffered cardiac arrest.
How similar studies have performed: Previous research has shown promising results with therapeutic hypothermia in adults, but this specific approach in children is novel and has not been extensively tested.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Moler, Frank W — University of Michigan at Ann Arbor
- Study coordinator: Moler, Frank W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.